Alzheimer's Assocation Research only
All of alz.org
  • Go to Alz.org
  • Research Center
  • AAIC
  • ISTAART
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Home
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2015


To view an abstract, select an author from the vertical list on the left.

2015 Grants - Yassine

Does APOE-e4 Genotype Reduce the Delivery of Fish Oil to the Brain?

Hussein N. Yassine, M.D.
University of Southern California
Los Angeles, California

2015 New Investigator Research Grant

Does an Alzheimer’s-related genetic variation reduce the beneficial effects of fish oil on brain health?

Background
One of the established risk factors for Alzheimer’s disease is a genetic variation of the apolipoprotein E gene known as (APOE-ɛ4). However, scientists have not yet identified the exact mechanisms by which APOE-ɛ4 increases dementia risk. Recent studies have shown that mice genetically engineered to carry the human APOE-ɛ4 gene have a defect in the ability to transport a certain molecule called docosahexaenoic acid (DHA) from the blood into the brain. DHA is found in fish oil, and is one of several essential fatty acids that have been shown to boost memory and other cognitive abilities. Moreover, these fatty acids are reduced in the brains of people with Alzheimer’s disease. Such findings suggest that APOE-ɛ4 may promote Alzheimer’s disease, in part, by hindering the beneficial effects of DHA on brain health.

Research Plan
Hussein N. Yassine, M.D., and colleagues have shown that people with the APOE-ɛ4 variation have lower DHA levels in their cerebrospinal fluid (the fluid surrounding the brain) suggesting impaired delivery of DHA from the diet into the brain. To further explore this hypothesis, the research team will administer a fish oil supplement to people with and without the APOE-ɛ4 variation and measure the participants’ DHA levels in the blood and cerebrospinal fluid before and after 6 weeks of treatment. The researchers expect that participants with the APOE-ɛ4 variation will show lower DHA levels in the cerebrospinal fluid revealing a chronic deficiency in brain DHA levels that could impact brain health.

Impact
Dr. Yassine’s study could reveal a novel mechanism underlying the increased dementia risk for people with the APOE-ɛ4 genotype — a mechanism that occurs well before clinical symptoms of Alzheimer’s become evident.


Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.